We are live on
!
Find out more
SCA
Signpost Capital Advisors Portfolio holdings
AUM
$34.2M
1-Year Est. Return
5.08%
This Fund
S&P 500
This Quarter
Est. Return
+7.44%
1 Year Est. Return
-5.08%
3 Year Est. Return
+24.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$264M
AUM Growth
+$27.7M
(+12%)
Cap. Flow
+$6.97M
Cap. Flow
% of AUM
2.64%
Top 10 Holdings %
Top 10 Hldgs %
85.49%
Holding
17
New
2
Increased
4
Reduced
2
Closed
3
Top Buys
| 1 |
Vanda Pharmaceuticals
VNDA
|
+$22.5M |
| 2 |
DF
Dean Foods Company
DF
|
+$13.6M |
| 3 |
ENDP
Endo International plc
ENDP
|
+$11.4M |
| 4 |
Cognizant
CTSH
|
+$8.04M |
| 5 |
AFSI
AmTrust Financial Services, Inc.
AFSI
|
+$339K |
Top Sells
| 1 |
Valero Energy
VLO
|
+$14M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13M |
| 3 |
WLL
Whiting Petroleum Corporation
WLL
|
+$12.4M |
| 4 |
Baidu
BIDU
|
+$8.8M |
| 5 |
SLCA
U.S. SILICA HOLDINGS, INC.
SLCA
|
+$809K |
Sector Composition
| 1 | Technology | 26.49% |
| 2 | Healthcare | 26.15% |
| 3 | Materials | 14.31% |
| 4 | Communication Services | 5.81% |
| 5 | Consumer Discretionary | 5.8% |
Similar funds
FREIGI
AGI
MMI
AS
SC
PLP
PIM
LWMG
Signpost Capital Advisors's Q2 2014 Portfolio in Review
As of Q2 2014, Signpost Capital Advisors held 17 positions worth $264M, up 12% from $236M the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Signpost Capital Advisors's Q2 2014 filing shows 2 new, 4 increased, 2 reduced and 3 closed positions. Its largest new stake was Vanda Pharmaceuticals: 1,688,952 shares worth $27.3M. The largest sale was Valero Energy, an estimated $14M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Healthcare and Materials.
- Signpost Capital Advisors's largest Q2 2014 buy was Vanda Pharmaceuticals: 1,688,952 shares worth $27.3M.
- Signpost Capital Advisors added most to Endo International plc in Q2 2014, an estimated $11.4M increase.
- Signpost Capital Advisors's biggest Q2 2014 reduction was Valero Energy, cutting an estimated $14M.
- Signpost Capital Advisors fully exited Regeneron Pharmaceuticals in Q2 2014, selling an estimated $13M.
- Signpost Capital Advisors's ten largest holdings make up 85% of its $264M portfolio in Q2 2014.
- Signpost Capital Advisors opened 2 new positions and closed 3 in Q2 2014.
- Signpost Capital Advisors's portfolio value rose 12% quarter-over-quarter to $264M.
Based on Signpost Capital Advisors's 13F filing for Q2 2014, filed 13 Aug 2014.